A 2-Part Multicenter Randomized Blinded Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis

Brief description of study

The purpose of this research study is to determine how effective the study treatment BIIB091 is in treating patients with Multiple Sclerosis (MS) alone and in conjunction with Diroximel Fumarate.

Clinical Study Identifier: s23-00646

ClinicalTrials.gov Identifier: NCT05798520

Principal Investigator: Mark Gudesblatt.

Other Investigators: Barbara A Bumstead, Wendy M Doroski, Myassar Zarif.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies